The forecasted treatment success rate for HIV-positive tuberculosis patients in the US shows a steady upward trend. It is expected to increase from 84% in 2024 to 87% by 2028. This indicates an improving trajectory, considering this rate stood at approximately 83% in 2023. The year-on-year growth rate reflects a consistent 1% increase from 2024 to 2027, with stability maintained in 2027 and 2028. The five-year compound annual growth rate (CAGR) suggests an average yearly increase of approximately 1%.
Future trends to watch include advancements in treatment protocols, the impact of new drug therapies, and healthcare policy changes that could further influence these success rates. Additionally, developments in personalized medicine may also contribute to this treatment success trend.
